stockportfolio.pro
ADMA Biologics, Inc. (ADMA)
Healthcare · Biotechnology · NasdaqGM
ADMA Biologics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.66M | $22.76M | $16.99M | $29.35M | $42.22M | $80.94M | $154.08M | $258.21M | $426.45M | $510.17M |
| Gross profit | $4.30M | $-6.40M | $-25.21M | $-10.16M | $-19.07M | $1.17M | $35.27M | $88.94M | $219.55M | $292.76M |
| Net income | $-19.52M | $-43.76M | $-65.74M | $-48.28M | $-75.75M | $-71.65M | $-65.90M | $-28.24M | $197.67M | $146.93M |
| Net margin | -183.1% | -192.3% | -387.1% | -164.5% | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
Source: ADMA Biologics, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of ADMA Biologics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ADMA in your portfolio →
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics, Inc. — frequently asked questions
What is ADMA Biologics, Inc.'s revenue?
ADMA Biologics, Inc. (ADMA) reported revenue of $510.17M for fiscal year 2025, up 19.6% from the prior year, according to its SEC filings.
Is ADMA Biologics, Inc. profitable?
Yes. ADMA earned net income of $146.93M in fiscal 2025, a net margin of 28.8%.
What is ADMA's P/E ratio?
ADMA Biologics, Inc. trades at a price-to-earnings ratio of about 12.4 based on the latest data in our nightly-refreshed cache.
How fast is ADMA Biologics, Inc. growing?
ADMA's revenue grew at roughly 64.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from ADMA Biologics, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.